Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance

Quantum Cyber N.V.

Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.
Proceeds to be used for settlement of outstanding liabilities and general corporate purposes.
Continues development of pancreatic cancer detection product and explores post-quantum cybersecurity.
Believes stockholders' equity exceeds $2.5M after receiving $6M total from preferred share sale (Feb & March 2026).
Previously wound down ColoAlert product and next-gen colorectal cancer screening development in Feb 2026.

item 1.01item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.